down arrow

AEON Biopharma, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US00791X1000
USD
0.67
-0.08 (-10.23%)

Dec 05

ASE

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.660.74

52 Week

0.3864.80
Valuation
Technical
Day's Volume

CASH

21.83 k

Shareholding (Mar 2025)

FII

4.03%

Held by 14 FIIs

DII

94.17%

Held by 2 DIIs

Promoter

0.00%

How big is AEON Biopharma, Inc.?

22-Jun-2025

As of Jun 18, AEON Biopharma, Inc. has a market capitalization of 8.65 million, categorizing it as a Micro Cap company, with reported net sales of 0.00 million and a net profit of 169.12 million over the latest four quarters. The company has shareholder's funds of -28.57 million and total assets of 3.14 million as of Dec 24.

Market Cap: As of Jun 18, AEON Biopharma, Inc. has a market capitalization of 8.65 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, AEON Biopharma, Inc. reported net sales of 0.00 million and a net profit of 169.12 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of -28.57 million and total assets of 3.14 million.

Read More

What does AEON Biopharma, Inc. do?

22-Jun-2025

AEON Biopharma, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting a net profit of $9 million for Q1 2025 and a market cap of $8.65 million. It has a negative P/E ratio, no dividend yield, and a high return on equity of 855.59%.

Overview: <BR>AEON Biopharma, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: 9 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 8.65 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.27 <BR>Return on Equity: 855.59% <BR>Price to Book: -0.76<BR><BR>Contact Details: <BR>Registrar Address: Not available.

Read More

Is AEON Biopharma, Inc. technically bullish or bearish?

20-Sep-2025

As of September 5, 2025, AEON Biopharma, Inc. is in a mildly bearish trend, influenced by daily moving averages and a bearish KST, despite some mild bullish signals from the weekly MACD and OBV, with a year-to-date return of -98.05% compared to the S&P 500's 12.22%.

As of 5 September 2025, the technical trend for AEON Biopharma, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating bearishness and a bearish KST on the monthly timeframe. While the weekly MACD and OBV show mild bullishness, the overall trend is influenced by the monthly Bollinger Bands and Dow Theory, both indicating mild bearishness. The stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -98.05% versus the benchmark's 12.22%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 8 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.44

stock-summary
Return on Equity

589.09%

stock-summary
Price to Book

-0.53

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-7 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-11.95%
0%
-11.95%
6 Months
-7.93%
0%
-7.93%
1 Year
-98.55%
0%
-98.55%
2 Years
-99.84%
0%
-99.84%
3 Years
-93.28%
0%
-93.28%
4 Years
-93.11%
0%
-93.11%
5 Years
0%
0%
0.0%

AEON Biopharma, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is AEON Biopharma, Inc. technically bullish or bearish?

As of 5 September 2025, the technical trend for AEON Biopharma, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating bearishness and a bearish KST on the monthly timeframe. While the weekly MACD and OBV show mild bullishness, the overall trend is influenced by the monthly Bollinger Bands and Dow Theory, both indicating mild bearishness. The stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -98.05% versus the benchmark's 12.22%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-301.05%
EBIT to Interest (avg)
-16.04
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.27
Sales to Capital Employed (avg)
0.01
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0.01%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.82
EV to EBIT
-0.58
EV to EBITDA
-0.58
EV to Capital Employed
-1.50
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Sideways
Bearish
Moving Averages
Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 5 Schemes (1.8%)

Foreign Institutions

Held by 14 Foreign Institutions (4.03%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -104.02% vs 4,307.69% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.30",
          "val2": "-7.70",
          "chgp": "44.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.40",
          "val2": "171.80",
          "chgp": "-101.40%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.60",
          "val2": "164.10",
          "chgp": "-104.02%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 110.92% vs -631.18% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-27.70",
          "val2": "-52.70",
          "chgp": "47.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "69.70",
          "val2": "-332.40",
          "chgp": "120.97%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "42.00",
          "val2": "-384.60",
          "chgp": "110.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-4.30
-7.70
44.16%
Interest
0.00
0.00
Exceptional Items
-2.40
171.80
-101.40%
Consolidate Net Profit
-6.60
164.10
-104.02%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -104.02% vs 4,307.69% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-27.70
-52.70
47.44%
Interest
0.00
0.00
Exceptional Items
69.70
-332.40
120.97%
Consolidate Net Profit
42.00
-384.60
110.92%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 110.92% vs -631.18% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About AEON Biopharma, Inc. stock-summary
stock-summary
AEON Biopharma, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."